Regulus Therapeutics (RGLS) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Regulus Therapeutics (RGLS) PT Raised to $1.37 at BMO Capital, Sees Shares 'Range-Bound'
March 8, 2018 5:52 AM ESTBMO Capital raised its price target on Regulus Therapeutics (NASDAQ: RGLS) to $1.37 (from $1.00) while maintaining a Market Perform rating.
"We believe investor focus will remain on the continued progress of Regulus's pipeline, particularly RG-012 for Alport syndrome where slower-than-expected enrollment and site... More
